Search Results 3971-3980 of 16510 for brca1%20and%20brca2%20genes%20and%20breast%20cancer

  1. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  2. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  3. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  4. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  5. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  6. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

    ... (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The ... * Documented germline or somatic mutation in BRCA1, BRCA2, or germline ...

  7. Niraparib + TSR042 In BRCA Mutated Breast Cancer - Mayo Clinic

    The purpose of this study is to evaluate pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations. The drugs are ...

  8. Clinical trials - Oncology (Medical)

    This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

  9. Clinical trials - Oncology (Medical)

    This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

  10. Clinical trials - Oncology (Medical)

    This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.